WebJun 27, 2022 · Show details. Anifrolumab. Albert Bui; Devang K. Sanghavi. Author Information and Affiliations. Last Update: June 27, 2022. Go to: Indications. Anifrolumab is one of three anti-type-1 interferon agents currently under investigation as a potential treatment for systemic lupus erythematosus (SLE).
DA:34PA:48MOZ Rank:43
Anifrolumab: Uses, Interactions, Mechanism of Action - DrugBank …
WebOct 20, 2016 · Anifrolumab is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. 7,11 It has a long duration of action as it is given every 4 weeks. 11 Patients should be counseled regarding the risks of serious infections, hypersensitivity ...
WebAnifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to IFNAR1, blocking the activity of type I interferons such as interferon-alpha and interferon-beta. 8 Anifrolumab also induces the internalization of IFNAR1, thereby reducing the number of receptors available for binding and reducing inflammation and immunological ...
WebAnifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor , blocking the activity of type I interferons such as interferon-α and interferon-β.
DA:94PA:81MOZ Rank:91
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
WebDec 18, 2019 · Abstract. Background. Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a...
DA:84PA:27MOZ Rank:98
Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus …
WebOct 26, 2023 · Anifrolumab, a human monoclonal antibody binding type I interferon receptor, has been recently approved by EMA and FDA for the treatment of SLE [ 1, 2, 3 ]. By targeting type I interferon signalling, anifrolumab tackles a key factor in the pathogenesis of SLE and CLE [ 13, 14 ].
DA:94PA:2MOZ Rank:46
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal ... - PubMed
WebPMID: 28130918. PMCID: PMC5299497. DOI: 10.1002/art.39962. Abstract. Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE).
DA:66PA:69MOZ Rank:27
Anifrolumab, a monoclonal antibody to the type I interferon …
WebAnifrolumab is a human monoclonal antibody to the type I IFN receptor subunit 1, which blocks the action of type I IFNs. Two phase 3 studies (TULIP-1 and TULIP-2) and a phase 2b study (MUSE) provide substantial evidence for the efficacy and safety of anifrolumab for moderately to severely active SLE.
DA:15PA:62MOZ Rank:14
Full article: Anifrolumab, a monoclonal antibody to the type I
WebJun 17, 2020 · Anifrolumab is a human monoclonal antibody to the type I IFN receptor subunit 1, which blocks the action of type I IFNs. Two phase 3 studies (TULIP-1 and TULIP-2) and a phase 2b study (MUSE) provide substantial evidence for the efficacy and safety of anifrolumab for moderately to severely active SLE.
DA:64PA:98MOZ Rank:1
FDA approval for anifrolumab in patients with lupus - The Lancet
WebOn July 30, 2021, the US Food and Drug Administration (FDA) issued its first new drug approval for systemic lupus erythematosus (SLE) in more than a decade. Approval of the drug—anifrolumab, a type 1 interferon receptor antagonist—was based on two phase 3 trials, TULIP-1 and TULIP-2.
